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Abstract
Objectives: To examine the impact of a two-part special edition of the 
Australian Broadcasting Corporation’s science journalism program Catalyst 
(titled Heart of the matter), aired in October 2013, that was critical of 
HMG-CoA reductase inhibitors (“statins”). 
Design, setting and participants: Population-based interrupted time-
series analysis of a 10% sample of Australian long-term concessional 
beneficiaries who were dispensed statins under the Pharmaceutical 
Benefits Scheme (about 51% of all people who were dispensed a statin 
between 1 July 2009 and 30 June 2014); dispensing of proton pump 
inhibitors (PPIs) was used as a comparator. 
Main outcome measures: Change in weekly dispensings and 
discontinuation of use of statins and PPIs, adjusting for seasonal and 
long-term trends, overall and (for statins only) stratified by the use of 
cardiovascular and diabetes medicines.
Results: In our sample, 191 833 people were dispensed an average of 26 946 
statins weekly. Following the Catalyst program, there was a 2.60% (95% 
CI, 1.40%–3.77%; P < 0.001) reduction in statin dispensing, equivalent to 
14 005 fewer dispensings Australia-wide every week. Dispensing decreased 
by 6.03% (95% CI, 3.73%–8.28%; P < 0.001) for people not dispensed 
other cardiovascular and diabetes medicines and 1.94% (0.42%–3.45%; 
P = 0.01) for those dispensed diabetes medicines. In the week the Catalyst 
program aired, there was a 28.8% (95% CI, 15.4%–43.7%; P < 0.001) 
increase in discontinuation of statin use, which decayed by 9% per week. 
An estimated 28 784 additional Australians ceased statin treatment. 
Discontinuation occurred regardless of the use of other cardiovascular and 
diabetes medicines. There were no significant changes in PPI use after the 
Catalyst program. 
Conclusions: Following airing of the Catalyst program, there was a 
temporary increase in discontinuation and a sustained decrease in 
overall statin dispensing. Up until 30 June 2014, there were 504 180 fewer 
dispensings of statins, and we estimate this to have affected 60 897 people.
The crux of the matter: did the ABC’s Catalyst 
program change statin use in Australia?
We found 
significant 
and sustained 
changes 
in statin 
dispensing 
following 
the airing of 
the Catalyst 
program
 On 24 and 31 October 2013, the Australian Broadcasting Corporation (ABC) aired a 
two-part special edition of the sci-
ence journalism series, Catalyst, titled 
Heart of the matter, that was critical 
of HMG-CoA reductase inhibitors 
(“statins”). The program questioned 
the link between high cholesterol 
levels and cardiovascular disease, 
and suggested that the benefits of 
statins had been overstated and the 
harms downplayed.1 Nearly 1.5 mil-
lion Australians are estimated to have 
viewed each part of the program.2
Statins are recommended nationally 
and internationally both for primary 
prevention of cardiovascular events 
in people at increased risk of cardio-
vascular disease, and for secondary 
prevention in those with established 
cardiovascular disease.3,4 They are the 
most commonly prescribed medicines 
in Australia,5 used by over 30% of the 
population aged 50 years and older.6
Considerable media debate and back-
lash from the medical community fol-
lowed the Catalyst program, including 
criticism for misleading patients.2,7 A 
National Heart Foundation survey 
of 1094 patients treated with lipid-
modifying medications found that 
11% of patients who watched Catalyst 
reported ceasing to take their choles-
terol medicines, an additional 12% 
stopped taking them but restarted, 
and 12% reported starting to use “nat-
ural remedies”.8 Moreover, a survey 
by the Australian Capital Territory 
Government of general practition-
ers and pharmacists found that 58% 
reported that some of their patients 
had stopped taking their statins after 
the Catalyst program.9 Our purpose 
in this study was to quantify any 
changes in the dispensing of statins 
after the airing of the Catalyst pro-
gram in October 2013. 
Methods
We used dispensing records from 
the Pharmaceutical Benefits Scheme 
(PBS) — under which all citizens and 
permanent residents of Australia 
are entitled to subsidised access to 
prescribed medicines — from 1 July 
2009 to 30 June 2014 for a 10% random 
sample of people who were dispensed 
a PBS-listed medicine. The 10% PBS 
sample is a standard dataset provid-
ed by the Australian Government 
Department of Human Services for 
analytical use, and is selected based 
on the last digit of each individual’s 
randomly assigned unique identifier. 
This dataset captures all dispensed 
PBS-listed medicines attracting a gov-
ernment subsidy, which occurs when 
the price of the medicine is above the 
PBS copayment threshold. To protect 
the privacy of people in this dataset, 
all dates of dispensing are offset ran-
domly by + 14 or − 14 days; the direc-
tion of the offset is the same for all 
records for each individual.
We restricted our analyses to people 
for whom we had a complete PBS 
dispensing history for the entire 
study period. As many commonly 
dispensed statins fall below the gen-
eral copayment threshold ($36.90 at 1 
January 2014), but above the conces-
sional copayment threshold ($6.00), 
we included only long-term conces-
sional beneficiaries (ie, individuals 
dispensed only medicines attracting 
a concessional copayment during 
the 5-year study period). Long-term 
concessional beneficiaries represent 
about 51% of all people who are dis-
pensed a statin, and consist of older 
people, those on a low income and 
the sick and disabled.
Medicines of interest
We included all doses (including 
combination products) of PBS-listed 
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statins (atorvastatin, fluvastatin, 
pravastatin, rosuvastatin and simv-
astatin) and proton pump inhibitors 
(PPIs; esomeprazole, lansoprazole, 
omeprazole, pantoprazole and rabe-
prazole). PPI dispensing was chosen 
as the comparator as these medicines 
are commonly dispensed and are 
used by a similar population as use 
statins. In addition, we expected that 
PPI dispensing would be unlikely to 
be affected by the Catalyst program. 
Measures
We defined discontinuation as the 
absence of any dispensing for a pe-
riod of at least three times the num-
ber of pills last dispensed (assuming 
one pill per day) plus a 5-day grace 
period. Nearly all statin dispensing 
records (99.5%) were for a 30-day sup-
ply; therefore, in most cases, a period 
of 105 days or more without a statin 
dispensing record was considered a 
discontinuation. The date of discon-
tinuation was the date that patients 
would have been expected to refill 
their prescriptions plus a 5-day grace 
period (ie, date of last dispensed sta-
tin + 35 days).
We classified individuals into four 
mutually exclusive risk categories. 
These were based on medicines 
dispensed for the treatment of 
cardiovascular disease (World 
Health Organization Anatomical 
Therapeutic Chemical [WHO ATC] 
codes C [excluding statins and topical 
agents for treating venous disorders] 
and B01AC), and diabetes (WHO ATC 
code A10). These risk categories were: 
(i) dispensed no other cardiac medi-
cines and no diabetes medicines; (ii) 
dispensed 1–2 other cardiac medi-
cines and no diabetes medicines; (iii) 
dispensed  3 other cardiac medi-
cines and no diabetes medicines; or 
(iv) dispensed at least one diabetes 
medicine.
Statistical analysis
We used an interrupted time-series 
analysis to assess the impact of the 
Catalyst program on dispensing and 
discontinuation of statins. The date of 
the first part of the Catalyst program 
(24 October 2013) was the change 
point. For each week, we summed 
the number of dispensing records 
and the number of individuals who 
discontinued for statins and for PPIs, 
overall and stratified by risk category 
(statins only). We defined a week as 
starting on Thursday, the day that 
Catalyst aired. Data were log-trans-
formed to estimate the percentage 
change.
PBS dispensing data are highly sea-
sonal;10 once an individual or family’s 
out-of-pocket PBS expenses exceed 
the PBS Safety Net threshold for a 
calendar year, all PBS medicines 
have a reduced copayment until 31 
December of that year. To account for 
this seasonal variability, as well as 
long-term trends and autocorrelation, 
we modelled the time series using 
an autoregressive integrated moving 
average (ARIMA) approach, using the 
Box–Jenkins method11 (Appendix). 
We created individual ARIMA mod-
els for overall dispensing (statins and 
PPIs), for discontinuation (statins and 
PPIs), and for dispensing and discon-
tinuation within each risk category 
(statins only).
We estimated the average number of 
dispensings of statins per week in 
Australia (including statins falling 
below the copayment) in the 3 months 
before the Catalyst program aired 
using publicly available aggregated 
dispensing data.12 These data were 
used to estimate the impact of the 
Catalyst program on all statin users, 
not just people included in the 10% 
PBS sample.
All analyses were performed in SAS, 
version 9.3 (SAS Institute Inc), and 
Stata, version 12 (Statacorp).
The study was approved by the 
New South Wales Population and 
Health Services Ethics Committee 
(2013/11/494) and the Department of 
Human Services External Request 
Evaluation Committee.
Results
In our sample, 191 833 people were 
dispensed a statin from 1 July 2009 
to 30 June 2014, with a mean of 26 946 
statin dispensings weekly (range, 
23 505 to 30 465). The average age of 
statin users in our study sample in 
2013 was 72 years (SD, 12 years), and 
55% were women. Thirteen per cent 
of our study population were dis-
pensed no other cardiac or diabetes 
medicines, 25% were dispensed 1–2 
cardiac medicines and no diabetes 
medicines, 36% were dispensed  3 
cardiac medicines and no diabetes 
medicines, and 27% were dispensed 
diabetes medicines (93% of whom 
were also dispensed at least one car-
diac medicine).
The overall trend in dispensing 
was relatively stable, with the high-
est dispensing counts in November 
and December, and lowest in January 
and February owing to individuals 
reaching their safety net threshold 
and preferentially refilling their pre-
scriptions more frequently at the end 
of the calendar year. Raw dispensing 
counts and counts adjusted for sea-
sonal variation are presented in Box 1 
(A). Rates of discontinuation follow 
a similar pattern, with an increase at 
the beginning of every year Box 1 (B).
1 Weekly unadjusted and seasonally adjusted (A) 
dispensing counts and (B) number of people 
discontinuing use of statins and proton pump 
inhibitors (PPIs), 1 July 2009 to 30 June 2014
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Dispensing
The week the Catalyst program was 
aired, we found a significant sus-
tained change of 2.60% fewer sta-
tin dispensings per week (Box 2). 
Given that there are an average of 
538 640 statin dispensings per week 
in Australia,12 this corresponds to an 
estimated decrease of 14 005 dispens-
ings per week in the Australian pop-
ulation. Assuming that most users 
are dispensed statins once a month, 
the equivalent of 60 897 Australians 
would be affected.
We found a significant reduction 
in the rate of statin dispensings in 
all risk categories (Box 2), with 6.0% 
fewer statin dispensings per week 
to people with no evidence of taking 
other cardiac or diabetes medicines 
and 1.9% fewer dispensings to those 
with evidence of taking diabetes 
medicines.
We also identified a decrease in statin 
dispensing of 1.96% (95% CI, 1.12%–
2.79%; P < 0.001) starting the week of 1 
March 2012, which coincided with the 
publication of a news story about the 
risk of diabetes and dementia associ-
ated with statin use;13 the level of sta-
tin dispensing returned to expected 
levels in March 2013. 
We found no significant change in 
the number of PPIs dispensings in 
the period following the Catalyst 
program (0.08%; 95% CI, − 1.53% to 
1.71%; P = 0.92).
Discontinuation
The number of people discontinu-
ing their use of statins increased by 
28.8% (P < 0.001) in the week that the 
Catalyst program aired, and this effect 
decayed by 9% (P < 0.001) per week, 
returning to average levels after 
18 weeks (Box 3). On average, 1.8% 
of statin users discontinued using 
statins each month before the Catalyst 
program aired; thus, following the 
Catalyst program, an estimated 28 784 
additional Australians discontinued 
their use of statins. A significant in-
crease in discontinuation was ob-
served regardless of the use of other 
cardiovascular and diabetes medica-
tions (Box 3).
In addition, we observed an increase 
in discontinuation after the 2012 news 
story,13 peaking at 29.0% (95% CI, 
19.1%–39.6%; P < 0.001) and decaying 
by 8% each week thereafter, lasting 
21 weeks.
There was no apparent change in PPI 
discontinuation following the airing 
of the Catalyst program.
Discussion
We found significant and sustained 
changes in statin dispensing follow-
ing the airing of the Catalyst program 
— 2.6% fewer statins were dispensed 
every week (a total of 504 180 fewer 
dispensings of statins), which equates 
to 60 897 Australians having been af-
fected up to 30 June 2014, as a result of 
increased discontinuation, decreased 
initiation and/or poor adherence. 
This includes an estimated 28 784 
additional people who discontinued 
their statins.
On average, among all statin users, 
the number-needed-to-treat over 5 
years to prevent one major vascular 
event such as a myocardial infarction 
or stroke ranges from 21 (for those 
with pre-existing coronary heart 
disease) to 40 (for those without).14 
It is unclear how long the change in 
statin use that we observed is likely 
to last. If the 60 897 individuals we 
estimated to have been affected con-
tinue to be non-adherent, this could 
result in between 1522 and 2900 pre-
ventable, and potentially fatal, major 
vascular events. While statins have 
been shown to reduce cardiovascu-
lar events regardless of an individ-
ual’s absolute cardiovascular risk,15 
national guidelines recommend their 
use in those who have had a previous 
2 Autoregressive integrated moving average (ARIMA) modelling results* of the impact of 
the Catalyst program on statin dispensing
Population 
Mean weekly dispensings 
12 weeks before Catalyst 
Weekly change in number of dispensings 
% (95% CI) P
Overall 27 536 − 2.60 (− 3.77 to − 1.40) < 0.001
No cardiac or diabetes medicines 2 549 − 6.03 (− 8.28 to − 3.73) < 0.001
1–2 cardiac medicines and no 
diabetes medicines
6 602 − 2.77 (− 4.54 to − 1.06) 0.002
 3 cardiac medicines and no 
diabetes medicines
10 252 − 2.40 (− 3.34 to − 1.46) < 0.001
 Diabetes medicines 8 133 − 1.94 (− 3.45 to − 0.42) 0.01
* ARIMA specification, (3,1,1)(3,1,1)52.
3 Autoregressive integrated moving average (ARIMA) modelling results of the impact of the Catalyst program on the number of 
people who discontinued their use of statins
Population
Mean weekly number 
of discontinuers 12 
weeks before Catalyst
Peak change in discontinuation
Weekly 
decay
Duration 
of eff ect*
Time to 
peak % (95% CI) P
Overall† 576 0 weeks 28.8% (15.4% to 43.7%) < 0.001 9% 18 weeks
No cardiac or diabetes medicines† 87 0 weeks 72.2% (27.3% to 133.0%) < 0.001 16% 16 weeks
1–2 cardiac medicines and no diabetes medicines† 143 0 weeks 58.4% (28.6% to 95.1%) < 0.001 12% 20 weeks
 3 cardiac medicines and no diabetes medicines‡ 186 1 week 30.5% (11.1% to 53.3%) 0.001 13% 14 weeks
 Diabetes medicines† 161 2 weeks 38.6% (13.3% to 69.6%) 0.002 40% 5 weeks
* The impact was considered to have ended when it decayed to  5%. † ARIMA specification, (0,1,1)(0,1,1)52. ‡ ARIMA specification, (0,1,2)(0,1,2)52. 
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cardiovascular event and in those at 
moderate or high absolute cardiovas-
cular risk.16 There is evidence that, 
in Australia, statins are both under-
used in those at high risk and over-
used in those at low risk.17 Some of 
the observed reduction in use may 
result from patients at low absolute 
risk of cardiovascular disease ceas-
ing therapy.
However, individuals who did and did 
not concomitantly take cardiovascular 
and diabetes medications had reduced 
their use of statins after the Catalyst 
program aired. This includes individu-
als likely to be at high cardiovascular 
risk, such as those with diabetes; the 
proven and substantial efficacy of 
statins in this group means they can 
least afford to discontinue therapy.18,19
Many elements of the Catalyst pro-
gram’s contents were inconsistent 
with the recommendations of key 
medical advice about statins and 
cardiovascular disease3 and the ABC 
has since withdrawn the program, 
primarily on the grounds that it 
breached their impartiality stand-
ards.20 The program was watched 
by a substantial proportion of the 
Australian public and is likely to 
have influenced their beliefs about 
the risks and benefits of statins and 
the relationship between high cho-
lesterol and cardiovascular disease. 
Belief in the effectiveness of medica-
tion and the need for treatment are 
important predictors of adherence 
to lipid-lowering medications.21 The 
National Heart Foundation’s survey 
of users of lipid-modifying agents 
found that, compared with those who 
were unaware of the program, those 
who watched it were more likely to 
express concerns about taking their 
cholesterol medicines, and a desire 
to stop.8
Our study is not the first to show the 
impact of adverse media reports on 
prescribed medicine use in Australia. 
A 2007 television news program 
about the association between oste-
onecrosis of the jaw and bisphospho-
nate use was associated with 29 633 
fewer prescriptions.22 Further, our 
incidental finding of a reduction in 
statin dispensing in 2012 that coin-
cided with a news story about the 
risks of diabetes and dementia dem-
onstrates the long-lasting impact of 
such publicity; statin dispensing only 
returned to average levels after a year.
The strength of our study lies in the 
use of a representative sample of all 
Australians ever dispensed a PBS-
subsidised medicine, and the use of 
a long-term concessional beneficiary 
population, ensuring complete cap-
ture of statin dispensing. Analyses 
of time-series data can be problem-
atic because of high levels of auto-
correlation, underlying trends, and 
seasonality. While PBS dispensing 
data are particularly seasonal, the 
ARIMA approach is well established 
and ideally suited for dealing with 
these problems.11,23 Further, although 
the lack of change in PPI dispensing 
supports the idea that the changes in 
statin dispensing were in response to 
the Catalyst program, we cannot rule 
out other factors affecting dispensing 
behaviour during this study period. 
We also saw no change in non-sta-
tin lipid-lowering medicines (data 
not shown). We also did not know 
the exact dates of dispensing, as all 
dates were offset by 2 weeks, but this 
would be expected to bias our find-
ings towards the null. Lastly, while 
we categorised individuals based on 
other cardiovascular and diabetes 
medicines they were dispensed, it 
is not possible to know their true 
level of cardiovascular risk without 
additional information, such as blood 
pressure and smoking status, which 
was not available in our study.
We estimated the change in the 
use of statins after the airing of the 
Catalyst program in all Australians 
who were prescribed statins based 
on findings in our study sample. 
However, as the Australian non-
concession population is younger, 
has higher socioeconomic status, 
and is in better health than the long-
term concession population, they 
probably have a lower risk of car-
diovascular events and a higher risk 
of not adhering to their statin regi-
men. Consequently, we may have 
underestimated the population-level 
impact on dispensing.
As of mid 2014, there is no indication 
that the change in dispensing after 
the Catalyst program has abated. Even 
though the observed effect was rela-
tively small, the prevalence of statin 
use in Australia and the established 
efficacy of these drugs14,22 means 
that a large number of people are 
affected, and may suffer unneces-
sary consequences. The changes in 
statin use occurred despite warnings 
in the Catalyst program that its con-
tent should not be taken as medical 
advice, and public criticism of the 
program. The subsequent retraction 
of the program may counteract some 
of the apparent negative impact, but 
this remains to be seen.
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